



Published in final edited form as:

*Behav Brain Res.* 2020 August 05; 391: 112713. doi:10.1016/j.bbr.2020.112713.

## Inhibition of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) Activity Reverses Behavioral Deficits in a Rodent Model of Autism

Manavi Chatterjee<sup>1,4,\*</sup>, Priya Singh<sup>1</sup>, Jian Xu<sup>1,2</sup>, Paul J. Lombroso<sup>1,2,3</sup>, Pradeep K. Kurup<sup>1,5,\*</sup>

<sup>1</sup>Child Study Center, Yale University, 230 South Frontage Rd, New Haven, CT, 06520

<sup>2</sup>Department of Psychiatry, Yale University, 230 South Frontage Rd, New Haven, CT, 06520

<sup>3</sup>Department of Neuroscience, Yale University, 230 South Frontage Rd, New Haven, CT, 06520

<sup>4</sup>Department of Pharmacology, Yale University, 230 South Frontage Rd, New Haven, CT, 06520

<sup>5</sup>Department of Surgery, University of Alabama at Birmingham, 1900 University Blvd, Birmingham, AL 35233

### Abstract

Autism spectrum disorders (ASDs) are highly prevalent childhood illnesses characterized by impairments in communication, social behavior, and repetitive behaviors. Studies have found aberrant synaptic plasticity and neuronal connectivity during the early stages of brain development and have suggested that these contribute to an increased risk for ASD. STEP is a protein tyrosine phosphatase that regulates synaptic plasticity and is implicated in several cognitive disorders. Here we test the hypothesis that STEP may contribute to some of the aberrant behaviors present in the VPA-induced mouse model of ASD. In utero VPA exposure of pregnant dams results in autistic-like behavior in the pups, which is associated with a significant increase in the STEP expression in the prefrontal cortex. The elevated STEP protein levels are correlated with increased dephosphorylation of STEP substrates GluN2B, Pyk2 and ERK, suggesting upregulated STEP activity. Moreover, pharmacological inhibition of STEP rescues the sociability, repetitive and abnormal anxiety phenotypes commonly associated with ASD. These data suggest that STEP may play a role in the VPA model of ASD and STEP inhibition may have a potential therapeutic benefit in this model.

\*Corresponding authors: Manavi Chatterjee: manavi.chatterjee@yale.edu; Pradeep Kurup: pkurup@uabmc.edu.

Author contributions

MC, PKK and PJL conceived of and designed the experiments. JX and PKK performed drug injections and biochemistry. MC and PS performed in vivo drug administration and behavior experiments. MC, PKK and PJL interpreted the data. MC, JX, PKK and PJL helped write the manuscript. All authors approved the final version of the submitted manuscript.

Declarations of interest

None.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Keywords

Valproic acid; STEP; TC-2153; autism; repetitive behavior; social interaction

---

## 1. Introduction

Autism spectrum disorder (ASD) is a group of highly prevalent heterogeneous disorders with significant social and economic burden [1]. It is a developmental disorder characterized by social communication deficits in addition to repetitive behaviors and interests [2]. Despite its high prevalence, the molecular mechanisms contributing to ASD is not understood [3]. Deciphering the complex pathophysiology of ASD will have a major impact on the development of potential therapeutics to improve quality of life in patients as well as alleviate the burden to families.

In an effort to address these issues, several genetic and environmentally induced rodent models were developed [4]. Among these, the valproic acid (VPA) rodent model is widely used. VPA is a teratogen and epigenetic modifier used extensively as an epileptic drug in humans. Epidemiological data suggest that ingestion of VPA during pregnancy is associated with a higher incidence of autism in humans [5, 6]. VPA models have relevance in human ASDs based on population studies and phenocopy several brain abnormalities and behavioral deficits present in human autism [7, 8]. The VPA rodent model of autism is widely used because of its construct and face validity, and its ability to cause structural and behavioral deficits similar to those found in human autism [7]. Prenatal exposure of VPA in mice induce behavioral responses akin to autistic phenotypes in humans. They show increased repetitive behaviors or stereotypy, reduced social interactions and abnormal anxiety phenotypes [9].

Striatum-Enriched protein tyrosine Phosphatase (STEP) is a brain-enriched protein tyrosine phosphatase present in striatum and other brain regions [10, 11]. STEP normally opposes the development of synaptic strengthening through its ability to dephosphorylate and inactivate a number of synaptic proteins that include several protein kinases, ERK1/2, Pyk2, and Fyn [12–15]. In addition, STEP dephosphorylation of the ionotropic glutamate receptor subunits GluN2B and GluA2 results in internalization of NMDA and AMPA receptor complexes [16, 17]. In addition, STEP also plays a role in spine dynamics through dephosphorylation of a regulator of spine dynamics, SPIN90 [18, 19].

The regulation of key synaptic proteins by STEP explains its role in several disorders. STEP levels are increased in Alzheimer's disease [20], schizophrenia [21], and Parkinson's disease [22], and in neurodevelopmental disorders such as fragile X syndrome [23]. Several pathways, including glutamate, dopamine and brain-derived neurotrophic factor (BDNF) signaling, regulate STEP activity [10, 24], and some of these signaling pathways are implicated in ASD [25–27].

Previous studies have demonstrated that STEP expression is developmentally regulated in different brain regions from embryonic stage to adulthood [28]. However, whether STEP contributes to the pathophysiology in ASD models has not been tested. Here we test the

hypothesis that STEP plays a role in the VPA-induced mouse model of ASD. In addition, we evaluate whether a small molecule STEP inhibitor, TC-2153, reverses behavioral deficits commonly associated with autistic phenotypes.

## 2. Materials and methods

### 2.1 Animals and drug treatments

All protocols were approved by the Yale University Institutional Animal Care and Use Committee and strictly adhered to the NIH Guide for the Care and Use of Laboratory Animals. Time pregnant female C57/B16 mice were injected with either saline or VPA (Sigma-Aldrich, 600mg/kg, subcutaneous) on E12.5. The pregnant mice were housed singly and monitored until the pups were born. The pups were weaned at P22 and housed in groups of 2–5 in standard vented rack cages in a 12:12 h light: dark cycle with food and water available ad libitum. A total number of 72 male mice were used in the study. Male pups were either sacrificed for biochemistry at one-month age (cohort 1, n=7) or tested for behaviors (cohorts 2 and 3) (Figure 1).

8-(tri-fluoromethyl)-1,2,3,4,5-benzocycloheximide-6-amine hydrochloride (TC-2153; SigmaAldrich) or vehicle (5% DMSO in saline) was administered through intraperitoneal injection at 10 mg/kg three hours prior to testing paradigms, as these parameters allows for adequate brain penetration [29].

### 2.2 Behavior tests

Animals were tested at one-month age and were tested in the same order in behavioral tasks that included the marble burying, light/dark box, the three-chambered social choice task and grooming/rearing behaviors with a 7–10-day interval between tests (Figure 1). Drug treatments were assigned randomly on each test day. Behavior analysis was done using the ANY-maze tracking software to automate behavioral testing. The first behavioral cohort consisted of in utero saline (n=11) or VPA (n=8) exposed mice. Additional mice were added in the social chamber tasks so the total number of mice in this task were Saline =23 and VPA =16. The second behavioral cohort consisted of mice exposed to VPA and were treated with vehicle (n=8) or TC (n=8) 3hours prior to testing. Additional mice were used in the social tasks therefore the total number of mice in the social chamber task were Veh=17 and TC=12. The age of each mouse for behavioral tasks were consistent between the different cohorts.

**2.2.1 Light/dark box**—A plexiglass light/dark box (containing two equally-sized chambers joined by a small opening, where one side was clear and the other was black as well as covered with a black lid) was used to examine the aversion of mice to a brightly lit (i.e., anxiogenic) environments [30, 31]. Mice were placed in the light side of the light/dark box and were allowed to freely explore for 10 min. The time spent in each side were recorded using ANY-maze.

**2.2.2 Marble burying**—Mice were allowed to acclimate individually in a cage filled with 4 cm of fresh bedding for 15 minutes. Mice were then removed from the cage and 12 black marbles were placed equidistant in a 3x4 arrangement. Mice were then returned to the

same cage for 30 minutes. Following the 30-minute testing period, the number of marbles that were more than two-thirds covered with bedding were counted by a single blinded experimenter. After each testing period, the cage was cleaned with 70% ethanol, left to dry for 5 minutes, wiped down with a clean paper towel, and fresh bedding was then added. On completion, an overhead picture was captured. The percentage of each visible marble was quantified using ImageJ (version 1.43u; NIH). For each marble, the visible area was measured and compared with the area of a completely visible marble (control = 100% visible). If a marble was visible  $\geq 60\%$  of the control marble (i.e. buried at least 40%) were considered buried.

**2.2.3 Three-chambered social choice task**—Sociability was evaluated by using the three-chambered social choice task, wherein mice were habituated in an opaque, rectangular plexiglass box divided into three equal compartments, each with a small entry way. Post habituation, mice were given the option to socialize with a conspecific stranger mouse enclosed under an inverted wire cup on one side, or a cup alone on the other side. We recorded the activity in close proximity (front 25% of the mouse within 1-inch margin around the cup) to the cups/mice in each chamber using the Any-maze software.

**2.2.4 Grooming**—We analyzed repetitive behaviors in mice by scoring self-grooming time as previously described [32]. Each mouse was placed in a clean empty plastic cage for a 10-minute acclimation period without cage bedding (to avoid cage bed digging, a potentially competitive repetitive behavior). Following acclimation, mice were scored for cumulative time spent self-grooming and rearing episodes during a 10-minute testing period using a sideways digital camera. Between each testing period, the cage was cleaned with 70% ethanol, left to dry for 5 minutes, and wiped down with a clean paper towel.

## 2.3 Subcellular fractionation and Western blot analysis

Mice were sacrificed at one month for biochemical experiments. Cortical tissue was dissected from saline (n=3) or VPA (n=3) exposed mice. Tissue was homogenized in buffer containing (in mM): 10 Tris base, pH 7.6, 320 sucrose, 150 NaCl, 5 EDTA, 5 EGTA, 1 NaF, 1  $\text{Na}_3\text{VO}_4$ , 1 DTT, and protease inhibitor mixture (Roche). Homogenates were centrifuged at  $800 \times g$  to remove nuclei and large debris (P1), and crude synaptosomal membrane (P2) fractions were prepared by centrifugation of S1 at  $9200 \times g$  for 15 min. These fractions were protein estimated using BCA kit (Thermo Fischer). Proteins (30  $\mu\text{g}$ ) were loaded onto 8% (wt/vol) SDS/PAGE gels and transferred to nitrocellulose membranes, blotted with primary antibodies overnight at  $4^\circ\text{C}$ , followed by incubation with secondary antibody. Bands were visualized by chemiluminescence, using a G:BOX system with GeneSnap image program and quantified using Image J 1.33 (NIH).

## 2.4 Statistical analysis

All data are represented as mean  $\pm$  SD. Statistical differences were determined using student-t test using GraphPad Prism software.  $P < 0.05$  was considered significant.

### 3. Results

#### 3.1 Administration of VPA in utero induced ASD phenotypes in pups

We first characterized the behavioral responses that are key to ASD phenotypes. We tested one-month old saline and VPA-exposed pups to light dark, marble burying, grooming and social interaction tasks. In agreement with previous papers [33, 34], VPA-exposed mice showed a significant increase in time spent in the light chamber of the box ( $t=2.172$ ,  $df=17$ ,  $p<0.05$ ) in comparison to saline-exposed mice (Fig 2A). VPA-exposed mice also buried significantly more marbles ( $t=3.845$ ,  $df=17$ ,  $p<0.05$ , Fig 2B) and spend more time grooming ( $t=2.668$ ,  $df=17$ ,  $p<0.05$ , Fig 2C) compared to the saline-exposed controls. Rearing time was significantly reduced in these mice ( $t=2.462$ ,  $df=17$ ,  $p<0.05$ , Fig 2D). Furthermore, in the three-chambered task of social interaction, VPA-exposed mice spend significantly less time in the chamber containing a stranger mouse ( $t=2.245$ ,  $df=36$ ,  $p<0.05$ , Fig 2E). They display no preference for the social chamber whereas the control mouse shows a significant preference ( $t=1.363$ ,  $df=16$ , Fig 2F) towards the chamber containing the mouse versus the empty chamber. VPA-exposed mice also spend significantly less time in close proximity to the stranger mouse ( $t=2.24$ ,  $df=36$ ,  $p<0.05$ , Fig 2G).

#### 3.2 Administration of VPA in utero leads to increased STEP61 activity in pups

Previous studies show disrupted synaptic development in pre-frontal cortex after VPA treatment in rodents [35, 36]. We therefore determined total STEP<sub>61</sub> levels in pre-frontal cortex after pre-natal VPA-exposure in mice at one-month age by immunoblot analysis. There was a significant ( $t=4.127$ ,  $df=4$ ,  $p<0.05$ ) increase in STEP<sub>61</sub> levels in mice exposed to VPA prenatally and a decrease in the tyrosine phosphorylation of the STEP substrates, GluN2B ( $t=13.59$ ,  $df=4$ ,  $p<0.001$ ), Pyk2 ( $t=8.032$ ,  $df=4$ ,  $p<0.01$ ) and ERK ( $t=3.348$ ,  $df=4$ ,  $p<0.05$ ) (Fig 3).

#### 3.3 Inhibition of STEP rescues ASD phenotypes in VPA exposed mice

We next assessed the effects of the STEP small molecule inhibitor TC-2153 on the behavioral phenotypes induced by VPA exposure. TC-2153 administration rescued the abnormal anxiety phenotype by significantly reducing the time spent in light chamber as compared to the vehicle treated VPA exposed mice ( $t=2.288$ ,  $df=14$ ,  $p<0.05$ , Fig 4A). Administration of TC-2153 also reduced the repetitive behaviors by reducing the number of marbles buried as compared to the vehicle treated group ( $t=2.481$ ,  $df=14$ ,  $p<0.05$ , Fig 4B). TC-2153 treatment also reduced the duration of grooming ( $t=3.267$ ,  $df=14$ ,  $p<0.01$  Fig 4C); however, it had no significant effects in rearing duration ( $t=0.6669$ ,  $df=14$ , Fig 4D). In the sociability tasks, TC-2153-treated mice (exposed to VPA) spent significantly more time in the social chamber ( $t=3.391$ ,  $df=27$ ,  $p<0.01$ , Fig 4E). They also showed a significant preference ( $t=7.405$ ,  $df=11$ ,  $p<0.001$ ) towards the social chamber versus the empty cup compared to the vehicle treated VPA mice ( $t=7.405$ ,  $df=11$ ,  $p<0.001$ , Fig 4F). Furthermore, the time spent in close proximity was also increased in the TC-2153 mice as compared to vehicle-treated VPA controls ( $t=3.034$ ,  $df=27$ ,  $p<0.01$ , Fig 4G).

## 4. Discussion

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder with known genetic, environmental, and epigenetic etiologies [2]. A major hypothesis in the field is that ASD is characterized by aberrant neuronal trajectory during early stages of development, which leads to subsequent functional alterations in neuronal regional connectivity [37, 38].

We explored the role of STEP in the VPA-exposed mice model of autism. In utero exposure of VPA leads to behavioral abnormalities in rodents that are similar to some ASD phenotypes [4, 8]. In agreement with earlier studies, we found that VPA-exposed mice showed reduced social preference, increased repetitive behaviors, and abnormal anxiety behaviors (Fig 2) [5, 9, 33, 39, 40]. STEP61 levels were upregulated in the prefrontal cortex regions in mice exposed prenatally to VPA (Fig 3). The increase in STEP correlates with a decrease in the tyrosine phosphorylation of its substrates (ERK, Pyk2, GluN2B) (Fig 3). Pharmacological reduction of STEP activity rescued the behavioral phenotypes induced by in utero VPA-exposure (Fig 4).

The rationale for studying STEP stems from its role in fragile X syndrome (FXS), which shares a significant overlap with ASD [41]. Increased STEP activity has been observed in Fmr1 KO mice. Fragile X mental retardation protein (FMRP) directly interacts with STEP mRNA [42] and regulates STEP expression levels [23]. Fmr1 KO mice have higher levels of STEP and both genetic reduction and pharmacologic inhibition of STEP reversed some of the phenotypic deficits in the mouse model of FXS, including social impairments that were present [23, 43].

A similar increase in STEP<sub>61</sub> expression is observed in the VPA-exposed pups. VPA being an epigenetic modulator and an inhibitor of histone deacetylase (HDAC), has been known to modulate the expression of multiple genes [44]. It could be possible that VPA alters the expression of STEP at a transcriptional level. Further studies are needed to test the hypothesis. Another possibility could be that the increase in STEP<sub>61</sub> expression is due to reduction of BDNF expression [45], as reported in patients as well as animals exposed to VPA [5, 46]. Previous studies from the lab show that STEP and BDNF share a reciprocal relationship. BDNF/Trk B signaling pathways promotes the ubiquitination and degradation of STEP [24, 45] and thereby reduces STEP levels. In addition, STEP regulates BDNF expression through ERK/CREB pathway [47]. Moreover, the STEP inhibitor, TC-2153, increases BDNF gene expression [48].

STEP accumulation and overactivation may have several downstream effects. For instance, STEP expression is critical during the development of midbrain dopaminergic neurons and mediates D2-induced ERK activation [28]. Overactivation of STEP in VPA-exposed mice might lead to reduced ERK signaling in these neurons. Disruption in ERK signaling during this critical neurodevelopment period is known to cause social impairment, increased anxiety and grooming behaviors in mice later in adulthood [49]. Recent studies have also found higher dopamine turnover in VPA-exposed mice [50]. Since co-activation of D1 and D2 receptors are implicated in social deficits [51] and D2 receptors control DA release and neurotransmission [52, 53], it is possible that the reduction of D2/ERK signaling due to

overactivation of STEP results in increased DA firing through co-activation of D1 and D2-R coactivation as a feedback mechanism. Moreover, STEP leads to the dephosphorylation of the GluN2B subunit of NMDA receptor, leading to the internalization of NMDA receptor complexes. Loss of glutamatergic proteins has been associated with social impairments in VPA-exposed mice [54].

In conclusion, we report that inhibition of STEP activity attenuates social and behavioral deficits in the VPA model of autism in mice. These pre-clinical experiments need to be expanded by longitudinal and electrophysiological studies to further our understanding of the role of STEP in ASD.

## Acknowledgments

We thank Marija Kamceva for technical support and other laboratory members for helpful discussions.

### Funding

This work was supported by the National Institutes of Health grants MH091037 and MH52711 (P.J.L.), and a Swebilius Award and NARSAD grant (M.C.).

## References

- [1]. Lavelle TA, Weinstein MC, Newhouse JP, Munir K, Kuhlthau KA, Prosser LA. Economic burden of childhood autism spectrum disorders. *Pediatrics*. 2014;133:e520–9. [PubMed: 24515505]
- [2]. Fakhoury M. Autistic spectrum disorders: A review of clinical features, theories and diagnosis. *Int J Dev Neurosci*. 2015;43:70–7. [PubMed: 25862937]
- [3]. Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warren Z, et al. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014. *MMWR Surveill Summ* 2018;67:1–23.
- [4]. Ergaz Z, Weinstein-Fudim L, Ornoy A. Genetic and non-genetic animal models for autism spectrum disorders (ASD). *Reprod Toxicol* 2016;64:116–40. [PubMed: 27142188]
- [5]. Roulet FI, Wollaston L, Decatanzaro D, Foster JA. Behavioral and molecular changes in the mouse in response to prenatal exposure to the anti-epileptic drug valproic acid. *Neuroscience*. 2010;170:514–22. [PubMed: 20603192]
- [6]. Christensen J, Gronborg TK, Sorensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. *JAMA*. 2013;309:1696–703. [PubMed: 23613074]
- [7]. Mabunga DF, Gonzales EL, Kim JW, Kim KC, Shin CY. Exploring the Validity of Valproic Acid Animal Model of Autism. *Exp Neurobiol* 2015;24:285–300. [PubMed: 26713077]
- [8]. Roulet FI, Lai JK, Foster JA. In utero exposure to valproic acid and autism—a current review of clinical and animal studies. *Neurotoxicol Teratol*. 2013;36:47–56. [PubMed: 23395807]
- [9]. Schneider T, Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. *Neuropsychopharmacology*. 2005;30:80–9. [PubMed: 15238991]
- [10]. Goebel-Goody SM, Baum M, Paspalas CD, Fernandez SM, Carty NC, Kurup P, et al. Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. *Pharmacological reviews* 2012;64:65–87. [PubMed: 22090472]
- [11]. Kamceva M, Benedict J, Nairn AC, Lombroso PJ. Role of Striatal-Enriched Tyrosine Phosphatase in Neuronal Function. *Neural Plast* 2016;2016:8136925. [PubMed: 27190655]
- [12]. Nguyen TH, Liu J, Lombroso PJ. Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420. *J Biol Chem*. 2002;277:24274–9. [PubMed: 11983687]
- [13]. Venkitaramani DV, Paul S, Zhang Y, Kurup P, Ding L, Tressler L, et al. Knockout of striatal enriched protein tyrosine phosphatase in mice results in increased ERK1/2 phosphorylation. *Synapse*. 2009;63:69–81. [PubMed: 18932218]

- [14]. Xu J, Kurup P, Bartos JA, Patriarchi T, Hell JW, Lombroso PJ. Striatal-enriched protein tyrosine phosphatase (STEP) regulates Pyk2 kinase activity. *J Biol Chem*. 2012;287:20942–56. [PubMed: 22544749]
- [15]. Xu J, Kurup P, Foscue E, Lombroso PJ. Striatal-enriched protein tyrosine phosphatase regulates the PTPalpha/Fyn signaling pathway. *J Neurochem*. 2015;134:629–41. [PubMed: 25951993]
- [16]. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. *Nat Neurosci*. 2005;8:1051–8. [PubMed: 16025111]
- [17]. Zhang Y, Venkitaramani DV, Gladding CM, Zhang Y, Kurup P, Molnar E, et al. The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. *J Neurosci*. 2008;28:10561–6. [PubMed: 18923032]
- [18]. Chatterjee M, Kwon J, Benedict J, Kamceva M, Kurup P, Lombroso PJ. STEP inhibition prevents A $\beta$ -mediated damage in dendritic complexity and spine density in Alzheimer's disease. *bioRxiv*. 2020:2020.04.02.022749
- [19]. Cho IH, Lee MJ, Kim DH, Kim B, Bae J, Choi KY, et al. SPIN90 dephosphorylation is required for cofilin-mediated actin depolymerization in NMDA-stimulated hippocampal neurons. *Cell Mol Life Sci*. 2013;70:4369–83. [PubMed: 23765104]
- [20]. Kurup P, Zhang Y, Xu J, Venkitaramani DV, Haroutunian V, Greengard P, et al. Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. *J Neurosci*. 2010;30:5948–57. [PubMed: 20427654]
- [21]. Carty NC, Xu J, Kurup P, Brouillette J, Goebel-Goody SM, Austin DR, et al. The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. *Transl Psychiatry* 2012;2:e137.
- [22]. Kurup PK, Xu J, Videira RA, Ononenyi C, Baltazar G, Lombroso PJ, et al. STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease. *Proc Natl Acad Sci ET S A*. 2015;112:1202–7.
- [23]. Goebel-Goody SM, Wilson-Wallis ED, Royston S, Tagliatela SM, Naegele JR, Lombroso PJ. Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. *Genes Brain Behav*. 2012;11:586–600. [PubMed: 22405502]
- [24]. Saavedra A, Puigdemoll M, Tyebji S, Kurup P, Xu J, Gines S, et al. BDNF induces Striatal-Enriched Protein Tyrosine Phosphatase 61 Degradation Through the Proteasome. *Mol Neurobiol*. 2016;53:4261–73. [PubMed: 26223799]
- [25]. Correia CT, Coutinho AM, Sequeira AF, Sousa IG, Lourenco Venda L, Almeida JP, et al. Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism. *Genes Brain Behav*. 2010;9:841–8. [PubMed: 20662941]
- [26]. Choudhury PR, Lahiri S, Rajamma U. Glutamate mediated signaling in the pathophysiology of autism spectrum disorders. *Pharmacol Biochem Behav*. 2012;100:841–9. [PubMed: 21756930]
- [27]. Kriete T, Noelle DC. Dopamine and the development of executive dysfunction in autism spectrum disorders. *PLoS One*. 2015;10:e0121605. [PubMed: 25811610]
- [28]. Kim SY, Lee HJ, Kim YN, Yoon S, Lee JE, Sun W, et al. Striatal-enriched protein tyrosine phosphatase regulates dopaminergic neuronal development via extracellular signal-regulated kinase signaling. *Exp Neurol*. 2008;214:69–77. [PubMed: 18708052]
- [29]. Xu J, Chatterjee M, Baguley TD, Brouillette J, Kurup P, Ghosh D, et al. Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's disease. *PLoS Biol*. 2014;12:e1001923.
- [30]. Crawley J, Goodwin FK. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. *Pharmacol Biochem Behav*. 1980;13:167–70.
- [31]. Onaivi ES, Martin BR. Neuropharmacological and physiological validation of a computercontrolled two-compartment black and white box for the assessment of anxiety. *Prog Neuropsychopharmacol Biol Psychiatry*. 1989;13:963–76. [PubMed: 2573111]
- [32]. Mehta MV, Gandal MJ, Siegel SJ. mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism. *PLoS One*. 2011;6:e26077. [PubMed: 22016815]




- [33]. Cohen OS, Varlinskaya EI, Wilson CA, Glatt SJ, Mooney SM. Acute prenatal exposure to a moderate dose of valproic acid increases social behavior and alters gene expression in rats. *Int J Dev Neurosci.* 2013;31:740–50. [PubMed: 24055786]
- [34]. Kim H, Lim CS, Kaang BK. Neuronal mechanisms and circuits underlying repetitive behaviors in mouse models of autism spectrum disorder. *Behav Brain Funct.* 2016;12:3. [PubMed: 26790724]
- [35]. Courchesne E, Mouton PR, Calhoun ME, Semendeferi K, Ahrens-Barbeau C, Hallet MJ, et al. Neuron number and size in prefrontal cortex of children with autism. *JAMA.* 2011;306:2001–10. [PubMed: 22068992]
- [36]. Trutzer IM, Garcia-Cabezas MA, Zikopoulos B. Postnatal development and maturation of layer 1 in the lateral prefrontal cortex and its disruption in autism. *Acta Neuropathol Commun.* 2019;7:40. [PubMed: 30867066]
- [37]. Guo X, Chen H, Long Z, Duan X, Zhang Y, Chen H. Atypical developmental trajectory of local spontaneous brain activity in autism spectrum disorder. *Sci Rep.* 2017;7:39822. [PubMed: 28057930]
- [38]. Belmonte MK, Allen G, Beckel-Mitchener A, Boulanger LM, Carper RA, Webb SJ. Autism and abnormal development of brain connectivity. *J Neurosci.* 2004;24:9228–31. [PubMed: 15496656]
- [39]. Kim KC, Kim P, Go HS, Choi CS, Park JH, Kim HJ, et al. Male-specific alteration in excitatory post-synaptic development and social interaction in pre-natal valproic acid exposure model of autism spectrum disorder. *J Neurochem.* 2013;124:832–43. [PubMed: 23311691]
- [40]. Silverman JL, Yang M, Lord C, Crawley JN. Behavioural phenotyping assays for mouse models of autism. *Nat Rev Neurosci.* 2010;11:490–502. [PubMed: 20559336]
- [41]. Belmonte MK, Bourgeron T. Fragile X syndrome and autism at the intersection of genetic and neural networks. *Nat Neurosci.* 2006;9:1221–5. [PubMed: 17001341]
- [42]. Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell.* 2011;146:247–61. [PubMed: 21784246]
- [43]. Chatterjee M, Kurup PK, Lundbye CJ, Hugger Toft AK, Kwon J, Benedict J, et al. STEP inhibition reverses behavioral, electrophysiologic, and synaptic abnormalities in *Fmr1* KO mice. *Neuropharmacology.* 2018;128:43–53. [PubMed: 28943283]
- [44]. Bhatti UF, Williams AM, Georgoff PE, Alam HB. The 'Omics' of Epigenetic Modulation by Valproic Acid Treatment in Traumatic Brain Injury-What We Know and What the Future Holds. *Proteomics Clin Appl* 2019;13:e1900068.
- [45]. Xu J, Kurup P, Azkona G, Baguley TD, Saavedra A, Nairn AC, et al. Down-regulation of BDNF in cell and animal models increases striatal-enriched protein tyrosine phosphatase 61 (STEP61) levels. *J Neurochem.* 2016;136:285–94. [PubMed: 26316048]
- [46]. Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, Sekine Y, et al. Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. *Prog Neuropsychopharmacol Biol Psychiatry.* 2006;30:1529–31. [PubMed: 16876305]
- [47]. Xu J, Kurup P, Baguley TD, Foscue E, Ellman JA, Nairn AC, et al. Inhibition of the tyrosine phosphatase STEP61 restores BDNF expression and reverses motor and cognitive deficits in phencyclidine-treated mice. *Cell Mol Life Sci.* 2016;73:1503–14. [PubMed: 26450419]
- [48]. Kulikov AV, Tikhonova MA, Kulikova EA, Volcho KP, Khomenko TM, Salakhutdinov NF, et al. A new synthetic varacin analogue, 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153), decreased hereditary catalepsy and increased the BDNF gene expression in the hippocampus in mice. *Psychopharmacology (Berl)* 2012;221:469–78. [PubMed: 22127556]
- [49]. Yufune S, Satoh Y, Takamatsu I, Ohta H, Kobayashi Y, Takaenoki Y, et al. Transient Blockade of ERK Phosphorylation in the Critical Period Causes Autistic Phenotypes as an Adult in Mice. *Sci Rep* 2015;5:10252. [PubMed: 25993696]
- [50]. Campolongo M, Kazlauskas N, Falasco G, Urrutia L, Salgueiro N, Hocht C, et al. Sociability deficits after prenatal exposure to valproic acid are rescued by early social enrichment. *Mol Autism.* 2018;9:36. [PubMed: 29946415]

- [51]. Zenko M, Zhu Y, Dremencov E, Ren W, Xu L, Zhang X. Requirement for the endocannabinoid system in social interaction impairment induced by coactivation of dopamine D1 and D2 receptors in the piriform cortex. *J Neurosci Res.* 2011;89:1245–58. [PubMed: 21557291]
- [52]. Anzalone A, Lizardi-Ortiz JE, Ramos M, De Mei C, Hopf FW, Iaccarino C, et al. Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors. *J Neurosci.* 2012;32:9023–34. [PubMed: 22745501]
- [53]. Ford CP. The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. *Neuroscience.* 2014;282:13–22. [PubMed: 24463000]
- [54]. Chau DK, Choi AY, Yang W, Leung WN, Chan CW. Downregulation of glutamatergic and GABAergic proteins in valproic acid associated social impairment during adolescence in mice. *Behav Brain Res.* 2017;316:255–60. [PubMed: 27614006]


**Highlights**

- In utero valproic acid administration induced increased STEP expression in mice.
- Increased STEP activation led to dephosphorylation of GluN2B, Pyk2 and ERK1/2.
- STEP Inhibitor, TC-2153 rescued the autistic-like behaviors in VPA exposed pups.




**Figure 1: Timeline of drug injections and behavior experiments.**

Timed-pregnant mice were injected with VPA (600 mg/kg, s. c.) or saline at embryonic day 12.5 (E12.5). A group of mice were sacrificed at postnatal day 30 (P30) for biochemical analyses (Fig 3). Other mice were tested in behavioral studies (Figs 2 and 4) at the indicated time points. Some mice also received TC-2153 (i. p.) or vehicle administration 3 h prior to behavioral tests.




**Figure 2: In utero VPA exposure in mice leads to ASD phenotype in mice.**

In utero VPA or saline exposed mice were subjected to behavioral tasks that are common to ASD in mice. VPA mice spent more time in the light chamber in the light dark box (A) and buried more marble in the marble burying task (B). VPA exposed mice also showed increased grooming (C) and reduced rearing (D) duration. In the social chamber task, they spent significant less time in the social chamber (E), show no preference for social versus empty chambers (F) as well as spend lesser time in close proximity to stranger mice (G) (\* $p < 0.05$ , Student t-test,  $n=8-12$  per group).



**Figure 3: VPA increases STEP61 expression in cortical synaptosomal membrane fractions in mice.**

Immunoblot and quantification of STEP61 protein levels and phosphorylation levels of STEP substrates (GluN2B, Pyk2 and ERK1/2) in one-month old mice after prenatal exposure to saline or VPA in E12.5 mice. (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , Student t-test,  $n=3$  per group).



**Figure 4: STEP inhibitor TC-2153 attenuates ASD in VPA exposed mice.**

VPA exposed mice were pretreated with TC-2153 or vehicle, three hours prior to behavioral testing. TC-2153 treatment significantly reduced the time spent in light chambers in light dark task (A). TC-2153 also showed reduction in marble burying behaviors (B) as well as grooming duration (C) in the VPA mice as compared to vehicle treated mice. No significant differences were observed in the rearing duration (D). In the sociability task, TC-2153 treated VPA mice spent significantly more time in the social chamber (E) and showed increased preference for the social chamber as compared to the empty chamber (F). TC-2153 treated VPA mice also spent more time in the close proximity to the stranger mouse as compared to the vehicle treated VPA mice (G) (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , Student t-test,  $n=8-12$  per group).